Beam Therapeutics Inc. 8K

Beam Therapeutics reported Q2 2026 results, advanced multiple base-editing programs including initiating a pivotal BEAM-302 cohort and completing risto-cel BEACON dosing, and projected a cash runway into mid-2029.

Beam Therapeutics Inc. filed a Form 8-K to report its second quarter 2026 financial results and to provide a comprehensive business update, highlighting the first patient dosed in the global pivotal cohort of its BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency, completion of dosing for all adult and adolescent patients in the BEACON Phase 1/2 trial of risto-cel in sickle cell disease with a BLA submission targeted as early as year-end 2026, FDA clearance of the IND and initiation of clinical start-up activities for BEAM-304 in phenylketonuria, ongoing evaluation of BEAM-301 in GSDIa, and progress in next-generation hematology programs, while reporting a Q2 2026 net loss of $122.7 million on $1.2 billion of cash, cash equivalents and marketable securities, which together with an anticipated $200 million draw on its Sixth Street facility is expected to fund operations into mid-2029.

Filing Facts

CIK

1745999

Ticker

BEAM

Form

8K

Source Type

fda

Accession

0001193125-26-331522

Alert Tier

7